| Outcome Measures: |
Primary: Assessment of pharmacodynamic (PD) parameters in feces, Change from baseline in fecal sodium excretion, Baseline and on Day 55 and 56 (over 48 hours)|Assessment of pharmacodynamic (PD) parameters in feces, Change from baseline in fecal short-chain fatty acids (SCFA), Baseline and on Day 55 and 56 (over 48 hours)|Assessment of pharmacodynamic (PD) parameters in feces, Change from baseline in fecal pH, Baseline and on Day 55 and 56 (over 48 hours)|Assessment of PD parameters in urine, Change from baseline in 24-hour urinary glucose excretion, Baseline and on Day 56 (over 24 hours)|Assessment of PD parameters in urine, Change from baseline in 24-hour sodium excretion, Baseline and on Day 56 (over 24 hours)|Assessment of PD parameters in blood, 14 hour plasma glucose profile after standardized meals, Baseline and on Day 56|Assessment of PD parameters in blood, 14 hour plasma glucagon-like peptide 1 (GLP-1) profile after standardized meals, Baseline and on Day 56 | Secondary: Fasting metabolic laboratory panel, Change from baseline in fasting plasma glucose, Baseline and on Day 56|Ambulatory Blood Pressure Measurement (ABPM), Change from baseline in average 24h systolic arterial pressure, Baseline and on days 54 until Day 56|Cardiovascular parameters, Change from baseline in plasma aldosterone, Baseline and on Day 56|Pulse wave velocity, Change from baseline in carotid-femoral pulse wave velocity, Baseline and on Day 55|Continuous Glucose Monitoring (CGM), Change from baseline in average diurnal glucose, Baseline, last 3 days of treatment|Echocardiography, Change from baseline in left ventricular ejection fraction (LVEF), Baseline and on Day 54|Echocardiography, Change from baseline in left ventricular end-diastolic diameter, Baseline and on Day 54|Plasma Volume Measurement, Change from baseline in plasma volume, Baseline and on Day 54|Adverse events, Number of patients with reported adverse events, Over 15 weeks|Assessment of pharmacokinetic (PK) parameters: Cmax, Sotagliflozin: maximum plasma concentration observed (Cmax), 24 hours after last investigational medicinal product (IMP) administration|Assessment of pharmacokinetic (PK) parameters: Ctrough, Sotagliflozin: plasma concentration observed before administration during repeated dosing (Ctrough), 24 hours after last IMP administration|Assessment of pharmacokinetic (PK) parameters: AUCtau, Sotagliflozin: Area under the plasma concentration versus time curve calculated using the trapezoidal method over the dosing interval (AUCtau), 24 hours after last IMP administration|Assessment of pharmacokinetic (PK) parameters: tmax, Sotagliflozin: First time to reach Cmax (tmax), 24 hours after last IMP administration
|
